Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II neoantigen peptide study in bladder cancer
ChiCTR1900026050Phase 2Not yet recruiting
- Sponsor
- Shenzhen University Institute of Urology
- Start
- Jan 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neoantigen peptides in bladder cancer, sponsored by Shenzhen University Institute of Urology. Primary endpoints: Vital signs, Routine blood test and 19 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
neoantigen peptides
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR1900026050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026050.